Tech Company Financing Transactions

Xagenic Funding Round

Domain Associates, CTI Life Sciences Fund and Ontario Emerging Technologies Fund participated in a $20 million Series B funding round for Xagenic. The funding round was announced on 12/2/2013.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

55 York St. 1000
Toronto ON, M5J 1R7
Canada

Phone

(416) 363-1999

Website

www.xagenic.com

Email Address

[email protected]

Overview

Xagenic is a molecular diagnostics company developing a true point- of-care platform. Our aim is to enable on-demand, near patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of first consultation. This will dramatically improve patient care and reduce health care costs.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Shana Kelley

        

Chief Financial Officer

Edward Jonasson

        

Chief Operating Officer

Randall Wilhoite

        

VP - R & D

Graham Jack

        

Browse more venture capital transactions:

Prev: 12/2/2013: Visterra venture capital transaction
Next: 12/2/2013: Wildfang International venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to document every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary